整体纵向应变评估乳腺癌放疗所致心脏毒性的价值:系统综述和meta分析

徐晓飞, 张丽霞, 代贺阳, 陈凌云, 薛姣姣, 李庆霞

  1. 1. 河北医科大学研究生院,河北 石家庄 050017
    2. 河北省人民医院肿瘤四科,河北 石家庄 050051
    3. 华北理工大学研究生学院,河北 唐山 063210
  • 收稿日期:2022-06-23 修回日期:2022-10-13 出版日期:2022-10-30 发布日期:2022-11-29
  • 作者简介:徐晓飞(ORCID: 0000-0003-0236-2497),E-mail: xuxiaofei2543@163.com
  • 基金资助:
    河北省科技厅国际科技合作基地建设专项《乳腺癌特异性多靶点诊疗方案联合研发合作示范》(19392411D)

摘要/Abstract

摘要:

背景与目的:乳腺癌已超过肺癌成为全球最常见的恶性肿瘤。早期乳腺癌患者经过综合治疗可以获得较长的生存期,但放疗引起的心脏毒性可能会影响远期预后。因此,早期监测放疗相关心脏损伤对于改善乳腺癌患者生存期具有重要意义。斑点追踪超声心电图(speckle-tracking echocardiography,STE)是一项研究心肌变形的新技术,其中整体纵向应变(global longitudinal strain,GLS)是评估放疗所致早期心脏损伤的良好参数。本文旨在探讨GLS评估乳腺癌放疗所致心脏毒性的价值。 方法:计算机检索PubMed、EMBASE、Web of Science、Cochrane Library、万方及中国知网即中国知识基础设施工程(China National Knowledge Infrastructure,CNKI)数据库,检索时间为2010年1月—2022年3月,按照预先设定的纳入排除标准,筛选利用GLS、整体纵向应变率(global longitudinal strain rate,GLSr)及左心室射血分数(left ventricular ejection fraction,LVEF)评估乳腺癌放疗过程中及放疗后心肌功能变化。由2名研究者独立进行文献筛选、资料提取。采用Review Manager 5.4分析软件进行数据分析。结果:最终纳入9项研究,共涉及543例患者,meta分析结果显示,左侧乳腺癌患者LEVF在放疗后即刻轻微下降,WMD为-0.98,在放疗后6个月有所上升,WMD为-0.83,但仍低于基线水平。右侧乳腺癌放疗后LVEF几乎没有变化。左侧乳腺癌患者放疗后即刻、放疗后6周、6个月、12个月GLS显著下降,WMD分别为1.57、1.84、1.04、1.69,差异有统计学意义,各研究之间无显著异质性。而右侧乳腺癌放疗后GLS无显著变化。不同侧乳腺癌GLSr的变化相差不大。结论:GLS可能是左侧乳腺癌患者放射治疗所致心脏损伤的较好预测指标。

关键词: 乳腺癌, 斑点追踪超声心动图, 放射治疗, 心脏毒性

Abstract:

Background and purpose: Breast cancer has overtaken lung cancer as the most common malignant tumor in women. Early breast cancer patient can achieve a long survival time after comprehensive treatment, however the cardiotoxicity caused by radiotherapy may affect its long-term prognosis. Therefore, early monitoring of radiation-induced heart disease is important for improving the survival of breast cancer patients. Speckle-tracking echocardiography (STE) is a new technique to study myocardial deformation. Global longitudinal strain (GLS) is a good parameter for evaluating early cardiotoxicity caused by radiotherapy. The purpose of this study was to evaluate the value of GLS in evaluating radiotherapy-induced early cardiotoxicity in breast cancer. Methods: PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang and China National Knowledge Infrastructure (CNKI) databases were searched by computer from January 2010 to March 2022. According to the pre-set inclusion and exclusion criteria, screening studies was performed using GLS and left ventricular ejection fraction (LVEF) to evaluate myocardial function changes during and after radiotherapy for breast cancer. Two researchers independently conducted literature screening and data extraction. Review Manager5.4 analysis software was used for data analysis. Results: Finally, 9 studies were included, involving a total of 543 patients. Meta-analysis results showed that LVEF of patients with left breast cancer decreased slightly immediately after radiotherapy, and WMD was -0.98. LVEF of those patients increased at 6 months after radiotherapy, and the WMD was -0.83, which was still lower than baseline. LVEF was almost unchangeable after radiotherapy for right breast cancer. GLS of left-sided breast cancer patients decreased significantly immediately after radiotherapy, at 6 weeks, 6 months and 12 months after radiotherapy, and WMD was 1.57, 1.84, 1.04 and 1.69, respectively. The differences were statistically significant. There was no significant heterogeneity among the studies. However, there was no significant change in GLS after radiotherapy for right breast cancer. There was no significant difference in GLSr between breast cancers of different sides. Conclusion: GLS may be a good predictor of radiation-induced heart disease in patients with left-sided breast cancer.

Key words: Breast cancer, Speckle-tracking echocardiography, Radiotherapy, Cardiotoxicity

中图分类号: 

相关文章

[1] 张景臣, 李新, 李江涛, 李海平, 陈艳丽, 牛冰, 祁川川, 叶贝贝. LINC02163靶向miR-338-3p影响乳腺癌细胞增殖、侵袭及迁移[J]. 中国癌症杂志, 2022, 32(9): 818-826.
[2] 中国抗癌协会乳腺癌专业委员会, 中国医师协会外科医师分会乳腺外科医师委员会, 上海市抗癌协会乳腺癌专业委员会. 乳腺肿瘤整形与乳房重建专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(9): 836-924.
[3] 肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
[4] 邱鹏飞, 王永胜. 前哨淋巴结时代乳腺癌的精准区域处理:演进与展望[J]. 中国癌症杂志, 2022, 32(8): 680-687.
[5] 张羽, 刘强. 液体活检在乳腺癌精准治疗中的应用进展及展望[J]. 中国癌症杂志, 2022, 32(8): 688-697.
[6] 周文斌, 谢晖, 丁强, 王水. 在乳腺癌局部精准治疗中的新进展:联合免疫治疗未来可期[J]. 中国癌症杂志, 2022, 32(8): 698-704.
[7] 刘燚铭, 范蕾, 莫淼, 邵志敏, 余科达. 卵巢功能抑制治疗雌激素受体阳性早期乳腺癌的短期效应和长期生存的影响因素分析[J]. 中国癌症杂志, 2022, 32(8): 705-711.
[8] 肖佳龙, 莫淼, 周昌明, 王泽洲, 沈洁, 袁晶, 余科达, 柳光宇, 吴炅, 沈镇宙, 邵志敏, 郑莹. 体重指数与年龄交互作用对乳腺癌患者预后影响的研究[J]. 中国癌症杂志, 2022, 32(8): 719-726.
[9] 陈安莉, 沈浩元, 阳仕雄, 邓春燕, 胡超华, 刘汉忠, 王舒, 钱芳. 血浆长链非编码RNA H19对乳腺癌新辅助治疗效果的预测价值[J]. 中国癌症杂志, 2022, 32(8): 727-735.
[10] 蔡钢, 王舒蓓, 陈佳艺. 放射治疗在胃癌全程管理中的现状与挑战[J]. 中国癌症杂志, 2022, 32(7): 581-587.
[11] 刘强, 方仪, 王靖. 单细胞测序技术在乳腺癌研究中的应用进展[J]. 中国癌症杂志, 2022, 32(7): 635-642.
[12] 钱瑶(综述), 刘锋(审校). 乳腺癌新辅助内分泌治疗的研究进展及展望[J]. 中国癌症杂志, 2022, 32(7): 643-649.
[13] 虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗:现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498.
[14] 贾晓青, 孙晓寅, 蒋蓓琦, 梅章懿, 傅韵, 莊志刚. 类泛素化neddylation修饰调控乳腺癌中核纤层蛋白lamin B1的表达[J]. 中国癌症杂志, 2022, 32(6): 535-541.
[15] 刘建兰, 陈黛诗, 胡泓, 周冬仙, 胡锦涛. HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估[J]. 中国癌症杂志, 2022, 32(5): 417-426.